Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

News provided by

Apr 26, 2017, 10:15 ET

NEW YORK, April 26, 2017 /PRNewswire/ -- Summary
Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 60 and over – a high-risk age range for lung cancer. Over half of the incident cases of non-small cell lung cancer (NSCLC) are diagnosed in patients over the age of 65. The percentage of people above 65 in 2016 and 2014 was 27.2% and 25.8% in Japan; 10.3% and 9.6% in China; 6% and 5.8% in India; 15.8% and 15% in Australia; and 13.5% and 13% in South Korea. The increase in the ageing population will drive NSCLC prevalence. Smoking is the main cause of lung cancer, ahead of radon gas, inhalation of chemical carcinogens and genetic factors. Although the number of smokers is falling in Asia-Pacific (APAC), the prevalence of NSCLC is increasing.

Read the full report: http://www.reportlinker.com/p03876504/Non-Small-Cell-Lung-Cancer-Therapeutics-in-Asia-Pacific-Markets-to-Launch-of-Premium-Targeted-Therapies-and-Increasing-Prevalence-to-Drive-the-Market.html

The NSCLC market in Asia-Pacific is forecast to grow substantially, from $3 billion in 2016 to $6.2 billion in 2023, at a compound annual growth rate (CAGR) of 10.8%. As per Gayathri Kanika, GBI Research, "Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region." The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023.

New targeted and immuno-therapies will drive market growth due to premium pricing and strong clinical performances, but they will also increase the degree of NSCLC market segmentation and the complexity of the treatment algorithm, owing to their enhanced efficacy in specific patient populations. The limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous therapies will not be offset by generic erosion; instead, premium therapies will occupy a larger market share for much of the forecast period in APAC.

The rate of mutation testing is very low in China and India compared with Australia, South Korea and Japan, and this makes many patients ineligible to receive targeted therapies. However, it is increasing, driven by increasing awareness among the healthcare fraternity. Hence, targeted therapies are expected to be used more often, driving market growth. Moreover, healthcare access and awareness have improved in India and China due to government initiatives. This will increase the market size by strengthening the treatment pool.

The report "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" provides the following -
- Detailed analysis of the products currently marketed for NSCLC, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
- Provides detailed analysis of the pipeline for NSCLC by stage of development, molecule type, program type, mechanism of action and molecular target and also analyzes recent clinical trials in this indication by enrollment, duration and failure rate, and provides a primary endpoint analysis of NSCLC clinical trials.
- Market forecasts for the NSCLC market, covering epidemiology, treatment usage patterns, pricing and market size for the 2016–2023 forecast period. Five APAC markets –India, China, Australia, South Korea and Japan– are covered, and data are presented at a country-by-country level, with further analysis of key market drivers and barriers.
- It describes the major deals that have taken place in the APAC NSCLC market in recent years.

Scope
The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.
- How will immunotherapies such as atezolizumab contribute to growth?
- What effect will patent expirations of currently branded therapies have on market value?
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
Read the full report: http://www.reportlinker.com/p03876504/Non-Small-Cell-Lung-Cancer-Therapeutics-in-Asia-Pacific-Markets-to-Launch-of-Premium-Targeted-Therapies-and-Increasing-Prevalence-to-Drive-the-Market.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001